Rheumatoid Arthritis
Conditions
Keywords
Electrical stimulation, inflammation, active implantable medical device, Laparoscopy, antirheumatic agents, autonomic nervous system, feasibility studies
Brief summary
This study will evaluate the safety and tolerability of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). Five participants will be implanted with the device and receive neurostimulation for 12 weeks.
Detailed description
The study will be an open-label single-arm study to evaluate the safety and tolerability of Galvani's neuromodulation system. Participants with active rheumatoid arthritis (RA) will be implanted with the Galvani system and receive active stimulation for 12 weeks. The total study duration in the study for each participant is approximately 5 months, with a 4-week screening period, 4 weeks recovery from surgery and a 12-week 'treatment' period. The participants will return to the clinic on pre-defined days for follow-up visits during the trial period. At Days 42 and/or Day 56, if study participants are not responding to stimulation, stimulation parameters might be adapted. At the end of the study (Day-84), participants will enroll in a long-term follow-up study up to 5-years after enrollment in this study.
Interventions
DEVICEActive Stimulation
The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
Sponsors
NAMSA
Galvani Bioelectronics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult-onset RA of at least six months duration * Male or female participants, 22-75 years of age * Active RA * Inadequate Response to at least 2 biologic DMARDs and/or JAK- inhibitors (JAKis) * Have an appropriate washout from previously used biological DMARDs or JAKi * A female participant should have no child-bearing potential
Exclusion criteria
* Inability to provide informed consent. * Significant psychiatric disease or substance abuse. * History of unilateral or bilateral vagotomy. * Active or latent tuberculosis * Known infection with human immunodeficiency virus (HIV); current acute or chronic hepatitis B or hepatitis C; previous hepatitis B. * Currently implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators). * Previous splenectomy * Any investigational small molecule drug or biological within 2 weeks or 2 half-lives whichever is longer, before surgery. * Uncontrolled other inflammatory diseases * Current/recurrent infections that in the opinion of the PI risk\>benefit. * History of cancer within the past 5 years, except non-malignant skin cancer. * Chronic use of morphine or oxicodone
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of the Galvani system | 12 weeks | Incidence and relatedness of Adverse Events (AEs), which include clinically significant findings from Laboratory Safety Assessments (clinical chemistry and hematology), vital signs (blood pressure, heart rate, respiratory rate, and body temperature), and 12-Lead ECG |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the usability of the external Galvani System devices and accessories | 12 weeks | Summarize feedback collected on questionnaires pertaining to the use of the external Galvani System devices |
| To evaluate the participants' perception of therapy and sensation | 12 weeks | Summarize feedback collected on questionnaires |
| Evaluate device performance | 12 weeks | Tabulation of device deficiencies |
| Effect of stimulation on the change in pharmacodynamic and response biomarkers | Day 1 to week 12 | Changes from baseline (Day 1) in the levels of LPS-inducible cytokine/ chemokine release, in whole blood assay at different timepoints after start of stimulation |
Countries
Netherlands, United Kingdom
Contacts
Primary ContactOperations Director
Outcome results
None listed